Q-omics provides the consensus-scored ZC3H12B profile across patient tissues and cancer cell-line models. ZC3H12B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZC3H12B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZC3H12B RNA expression shows 20,788 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, KICH, and KIRP as cancer lineages where ZC3H12B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H12B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H12B survival associations across molecular data types. ZC3H12B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H12B RNA expression–survival associations across cancer types. High ZC3H12B expression shows favorable associations in HNSC, SKCM, PAAD, MESO, LGG and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZC3H12B RNA expression.
This table summarizes ZC3H12B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZC3H12B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H12B shows lower tumor expression in KICH, KIRC, UCEC, THCA, LUSC and BLCA. The KICH box plot shows higher ZC3H12B RNA expression in normal versus tumor tissue (log2 FC = −1.198, t-test p < 0.001).
This table shows molecular features associated with ZC3H12B in patient tissues and cancer cell lines. In patient samples, ZC3H12B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H12B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
